CAMBRIDGE, Mass.--(BUSINESS WIRE)--HiFiBiO Therapeutics, a clinical stage biotechnology company focused on immune modulation, today announced that the U.S. Food and Drug Administration (FDA) has ...

One of the primary objectives for the application of flow cytometry in any testing environment should be measurement assurance, i.e., the generation of reliable and reproducible results. This goal can ...

Co announces the publication of a new discovery of the properties of Curaxin CBLC102 (Quinacrine), CBLI's lead anti-cancer drug candidate, in the current edition of the European Journal of Immunology.

The UAB Heersink School of Medicine Immunology Institute is also committed to becoming a nexus for those interested in educating our campus, our community and our state on the critical role that the ...

Given its ability to isolate pathogens, nuclei, and immune cells for downstream applications, cell sorting is an essential tool for immunological studies. Yet, the potential for aerosol formation—and ...

HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in-Class BTLA Agonist Antibody for the Treatment of Inflammatory and Immunology Diseases HiFiBiO Therapeutics, a ...